Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Research & Development (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Research & Development data on record, last reported at $348000.0 in Q3 2025.

  • For Q3 2025, Research & Development rose 329.63% year-over-year to $348000.0; the TTM value through Sep 2025 reached $496000.0, up 95.28%, while the annual FY2024 figure was $286000.0, 81.12% down from the prior year.
  • Research & Development reached $348000.0 in Q3 2025 per CYCN's latest filing, up from $56000.0 in the prior quarter.
  • Across five years, Research & Development topped out at $12.1 million in Q2 2021 and bottomed at -$21.1 million in Q4 2022.
  • Average Research & Development over 5 years is $2.1 million, with a median of $348000.0 recorded in 2025.
  • Peak YoY movement for Research & Development: crashed 301.42% in 2022, then surged 329.63% in 2025.
  • A 5-year view of Research & Development shows it stood at $10.5 million in 2021, then tumbled by 301.42% to -$21.1 million in 2022, then soared by 100.11% to $24000.0 in 2023, then skyrocketed by 133.33% to $56000.0 in 2024, then skyrocketed by 521.43% to $348000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $348000.0 in Q3 2025, $56000.0 in Q2 2025, and $36000.0 in Q1 2025.